fbpx
/, Research/October CanDo News Review

October CanDo News Review

There’s a lot happening in the world of cancer research and other areas of interest to our users.  So we’re going to trial a weekly post of interesting links that we think you’d like to know about.  We’d love your feedback about what you’d like to hear more about so please get in touch.

Today’s news for your review!

Could environmental factors make prostate cancer more aggressive?

Our friends at the Garvan Institute of Medical Research, working with a collaborative multi-national team, have uncovered some fascinating news about prostate cancer, a genetic disease. They’ve discovered that the DNA of prostate cancer in African men,  differs from that of non-African men, making the tumours of African men more aggressive and difficult to treat. Why this is, or a potential cause is as yet unknown. One theory is a possible environmental carcinogen specific to Africa, that is as yet unidentified.  There’s much to study to try to understand this further.  Find out more here.

New hope for treatment of metastatic Triple Negative Breast Cancer

Our founder, Rachael, suffered early stage Triple Negative Breast Cancer and was successfully treated with surgery, chemotherapy and radiotherapy.  However outcomes for women with advanced TNBC remain poor versus other breast cancers with few options for women for whom chemotherapy does not work. Now researchers in the US have found that women with metastatic TNBC, treated with a combination of immunotherapy and chemotherapy, live longer than women treated with chemotherapy alone. The immunotherapy drug in the trial, helps T-Cells (a type of white blood cell) identify and attack cancer cells.  This piece in the New York Times explains why this is such an important finding for women who for many years have had few treatment options made available to them.

Sharing your cancer data to help others?  Count me in!

Time Magazine this week reported on a project called Count Me In, that asks cancer patients to allow access to medical information and pathology samples, to help create a large database that could be used to find patterns that may lead to important breakthroughs.  Being part of a large sample is especially important for rare cancer or cancers that are difficult to treat, to assist researchers in developing hypotheses and design studies that may eventually lead to cures.  The project is currently seeking data from US and Canadian patients with a view to 100,000 participants in the next few years.  For participants, the benefit is knowing that providing your data could help future cancer patients (a number expected to sky rocket in the next 20 years). I’ve never yet met a cancer patient who didn’t want to help others in some way, so what a great way to harness that energy!  Read more here. 

Thanks for reading this week’s News Review!

The CanDo app is supported by the Garvan Institute of Medical Research. When the question is “What can I do?”, CanDo helps turn empathy into action.

By |2018-10-28T21:43:46+00:00October 26th, 2018|News, Research|0 Comments

About the Author:

Rachael Lonergan is the founder of CanDo. She is an advertising executive, pet mum and enthusiastic but not-very-good yoga devotee who lives in Sydney, Australia.